Viatris is a new global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. Viatris's mission is to empower people worldwide to live healthier at every stage of life by providing access to medicines, advancing sustainable operations, developing innovative solutions, and leveraging our collective expertise to improve patient outcomes.
Viatris’ portfolio comprises >1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases. Viatris is headquartered in the U.S.